Joshua Silverman Nathaniel's most recent trade in PharmaCyte Biotech Inc was a trade of 40,000 Common Stock done at an average price of $0.8 . Disclosure was reported to the exchange on Jan. 5, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| PharmaCyte Biotech Inc | Joshua Nathaniel Silverman | Director, CEO and President | Purchase of securities on an exchange or from another person at price $ 0.83 per share. | 05 Jan 2026 | 40,000 | 416,250 | - | 0.8 | 33,316 | Common Stock |
| PharmaCyte Biotech Inc | Joshua Nathaniel Silverman | Director, CEO and President | Purchase of securities on an exchange or from another person at price $ 0.78 per share. | 05 Jan 2026 | 30,000 | 346,250 | - | 0.8 | 23,493 | Common Stock |
| PharmaCyte Biotech Inc | Joshua Nathaniel Silverman | Director, CEO and President | Purchase of securities on an exchange or from another person at price $ 0.79 per share. | 05 Jan 2026 | 30,000 | 376,250 | - | 0.8 | 23,667 | Common Stock |
| Petros Pharmaceuticals Inc | Joshua Silverman Nathaniel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 4,375,000 | 4,415,450 | - | 0 | Common Stock | |
| PharmaCyte Biotech Inc | Joshua Nathaniel Silverman | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2025 | 575,000 | 575,000 | - | 0 | Common Stock | |
| PharmaCyte Biotech Inc | Joshua Nathaniel Silverman | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.02 per share. | 12 Dec 2025 | 258,750 | 316,250 | - | 1.0 | 263,925 | Common Stock |
| TNF Pharma Inc | Joshua Nathaniel Silverman | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2025 | 91,356 | 100,029 | - | 0 | Common stock | |
| StableX Tech Inc | Joshua Nathaniel Silverman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Oct 2025 | 220,513 | 220,513 | - | - | Employee Stock Option (Right to Buy | |
| TNF Pharma Inc | Joshua Nathaniel Silverman | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2025 | 8,644 | 8,673 | - | 0 | Common stock | |
| Synaptogenix Inc | Joshua Nathaniel Silverman | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2025 | 100,000 | 126,681 | - | 0 | Common Stock, par value $0.0001 per share | |
| Synaptogenix Inc | Joshua Nathaniel Silverman | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.23 per share. | 06 Aug 2025 | 40,000 | 86,681 | - | 7.2 | 289,200 | Common Stock, par value $0.0001 per share |
| Synaptogenix Inc | Joshua Nathaniel Silverman | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2025 | 36,000 | 36,000 | - | - | Employee Stock Option (right to buy) | |
| Synaptogenix Inc | Joshua Nathaniel Silverman | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 41,919 | 43,449 | - | 0 | Common Stock, par value $0.0001 per share | |
| Synaptogenix Inc | Joshua Nathaniel Silverman | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.85 per share. | 30 Jun 2025 | 16,768 | 26,681 | - | 7.9 | 131,629 | Common Stock, par value $0.0001 per share |
| Femasys Inc | Joshua Nathaniel Silverman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2025 | 17,600 | 17,600 | - | - | Stock Option (Right to Buy) | |
| Petros Pharmaceuticals Inc | Joshua Nathaniel Silverman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 1,000,000 | 1,011,237 | - | 0 | Common Stock | |
| StableX Tech Inc | Joshua Nathaniel Silverman | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Dec 2024 | 146,052 | 189,323 | - | 0 | Common Stock | |
| StableX Tech Inc | Joshua Nathaniel Silverman | Director, Executive Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 97,368 | 97,368 | - | - | Cash-Settled Restricted Stock Units | |
| StableX Tech Inc | Joshua Nathaniel Silverman | Director, Executive Chairman | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Dec 2024 | 6,166 | 43,271 | - | 0 | Common Stock | |
| Femasys Inc | Joshua Nathaniel Silverman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jul 2024 | 17,600 | 17,600 | - | - | Stock Option (Right to Buy) | |
| Synaptogenix Inc | Joshua Nathaniel Silverman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Apr 2024 | 800 | 800 | - | - | Stock Option (Right to Buy) | |
| Petros Pharmaceuticals Inc | Joshua Silverman Nathaniel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| StableX Tech Inc | Joshua Nathaniel Silverman | Director | Sale of securities on an exchange or to another person at price $ 0.82 per share. | 01 Aug 2023 | 12,740 | 395,493 | - | 0.8 | 10,386 | Common Stock |
| TNF Pharma Inc | Joshua Nathaniel Silverman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 200,000 | 200,000 | - | - | Employee Stock Option (Right to Buy) | |
| Petros Pharmaceuticals Inc | Nathaniel Joshua Silverman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2023 | 6,722 | 0 | - | - | Restricted Stock Units | |
| Petros Pharmaceuticals Inc | Nathaniel Silverman Joshua | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2023 | 6,722 | 11,237 | - | - | Common Stock | |
| Petros Pharmaceuticals Inc | Joshua Nathaniel Silverman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Apr 2023 | 39,000 | 39,000 | - | - | Stock Option (Right to Buy) | |
| StableX Tech Inc | Joshua Nathaniel Silverman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2023 | 197,333 | 420,160 | - | 0 | Common Stock | |
| StableX Tech Inc | Joshua Nathaniel Silverman | Director | Sale of securities on an exchange or to another person at price $ 0.71 per share. | 30 Jan 2023 | 7,171 | 222,827 | - | 0.7 | 5,108 | Common Stock |
| Petros Pharmaceuticals Inc | Joshua Nathaniel Silverman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2023 | 2,515 | 4,515 | - | - | Common Stock | |
| Petros Pharmaceuticals Inc | Joshua Nathaniel Silverman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2023 | 2,515 | 0 | - | - | Restricted Stock Units | |
| Synaptogenix Inc | Joshua Nathaniel Silverman | Director | Sale of securities on an exchange or to another person at price $ 1.17 per share. | 16 Dec 2022 | 19,012 | 38,238 | - | 1.2 | 22,280 | Common Stock, par value $0.0001 per share |
| Synaptogenix Inc | Joshua Nathaniel Silverman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2022 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| StableX Tech Inc | Joshua Nathaniel Silverman | Director | Sale of securities on an exchange or to another person at price $ 0.82 per share. | 11 May 2022 | 12,855 | 237,169 | - | 0.8 | 10,541 | Common Stock |
| StableX Tech Inc | Joshua Nathaniel Silverman | Director | Sale of securities on an exchange or to another person at price $ 0.59 per share. | 11 May 2022 | 7,171 | 229,998 | - | 0.6 | 4,245 | Common Stock |
| Petros Pharmaceuticals Inc | Joshua Nathaniel Silverman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Apr 2022 | 67,227 | 67,227 | - | - | Restricted Stock Units | |
| StableX Tech Inc | Joshua Nathaniel Silverman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 114,729 | 250,024 | - | 0 | Common Stock | |
| Synaptogenix Inc | Joshua Nathaniel Silverman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jul 2021 | 42,250 | 57,250 | - | 0 | Common Stock, par value $0.0001 per share | |
| Synaptogenix Inc | Joshua Nathaniel Silverman | Director | Purchase of securities on an exchange or from another person at price $ 8.30 per share. | 14 Jun 2021 | 10,000 | 15,000 | - | 8.3 | 83,000 | Common Stock, par value $0.0001 per share |
| StableX Tech Inc | Joshua Nathaniel Silverman | Director | Sale of securities on an exchange or to another person at price $ 5.17 per share. | 04 Jun 2021 | 39,008 | 135,295 | - | 5.2 | 201,687 | Common Stock |
| Petros Pharmaceuticals Inc | Joshua Nathaniel Silverman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Apr 2021 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| StableX Tech Inc | Joshua Nathaniel Silverman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 42,000 | 174,303 | - | 0 | Common Stock |